By Timo Minssen We are pleased to announce a new publication in the International Review of Intellectual Property and Competition Law (IIC). Our paper analyzes new case law in European stem cell patenting and compares these developments with the US situation and International treaties. Further information and an abstract is available below: Authors: Ana Nordberg & Timo Minssen, University of Copenhagen, Centre…
By Dalia Deak The issue of drug pricing has been thrust center stage (again) after Turing Pharmaceuticals raised the price of daraprim from $13.50 to $750 per dose. The public issued a loud outcry, the pharmaceutical industry condemned the move, and presidential candidates are now discussing drug prices (as discussed previously on this blog). The reactions…
By Alex Stein Georgia’s Court of Appeals recently categorized a clinic’s front-desk person’s failure to communicate a patient’s complaints to the doctors as ordinary negligence rather than medical malpractice. Wong v. Chappell, 773 S.E.2d 496 (Ga.App. 2015). This categorization has four important implications: First, it allows an aggrieved patient to file her suit and proceed to trial…
By Timo Minssen I am happy to announce the following publications: 1) Minssen, Timo and Nordberg, A., The Evolution of the CJEU’s Case Law on Stem Cell Patents: Context, Outcome and Implications of Case C‑364/13 International Stem Cell Corporation (March 11, 2015). Available at SSRN: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=2576807 (under review for journal publication)Abstract: On 18th December 2014, the CJEU…
By Timo Minssen I am pleased to announce two new publications on (1) “European patent strategies under the UPCA” and (2) “Synthetic Biology & Intellectual Property Rights”: 1) Minssen, T & Lundqvist, B 2014, ‘The ”opt out” and “opt-in” provisions in the Unified Patent Court Agreement – Impact and strategies for European patent portfolios‘ ,…
By Timo Minssen In Part II of this blog on legal issues relating to the revival of phage therapy I discussed the US Supreme Court’s decisions in Myriad and Prometheus, which might present major obstacles to the patentability of phage-related technology (a more detailed analysis of the Myriad and Prometheus decisions is available here). Yet,…
By Timo Minssen Please find attached a ppt presentation on “New regulatory pathways and incentives for sustainable antibiotics: Recent European & US Initiatives” given on March 7, 2014 at the Broad Institute of MIT and Harvard. The presentation was followed by a discussion moderated by US patent attorney Melissa Hunter-Ensor, Partner at Saul Ewing, Boston. I…
Please join the HMS Division of Medical Ethics and Program in Ethics and Health for… “Strings Attached: Untangling the Ethics of Incentives” Ruth W. Grant, PhD Professor of Political Science and Philosophy, Duke University Thursday, February 28, 2013 12:00 – 1:15 PM HMS Division of Medical Ethics 1st Floor Conference Room 641 Huntington Avenue, Boston…
By Scott Burris No, I mean it: this is a question to Bill of Health readers who know about the law on this topic. This week, a colleague handed me a palm card she’d been given at a subway station here in Philadelphia. “Cash for diabetic test strips” it read. Comparing prices on the company’s…
By Nir Eyal Yesterday, Boston public radio station WBUR interviewed a Massachusetts primary care physician who refuses to admit new obese patients. She claims that it’s because she lacks proper equipment, but she seems to have mixed motives. Earlier she had admitted that it’s rather because she feels that if they don’t lose the weight, “I’m paying the cost of other people’s…
